NRAS tumor mutations are associated with reduced odds of dermatologic adverse events in patients with metastatic melanoma receiving immune checkpoint inhibitors

• Michael S. Chang, MD,
• Jordan T. Said, MD,
• Elliot H. Akama-Garren, PhD,
• Nicole Trepanowski, MD,
• Ai-Tram N. Bui, MD,
• Anita Giobbie-Hurder, MS,
• Nicole R. LeBoeuf, MD, MPH,
• Rebecca I. Hartman, MD, MPH

Affiliations

Michael S. Chang, MD

Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts

Jordan T. Said, MD

Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts

Elliot H. Akama-Garren, PhD

Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts

Nicole Trepanowski, MD

Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts; Boston University School of Medicine, Boston, Massachusetts

Ai-Tram N. Bui, MD

Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts

Anita Giobbie-Hurder, MS

Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts

Nicole R. LeBoeuf, MD, MPH

Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts; Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber/Brigham and Women’s Cancer Center, Boston, Massachusetts

Rebecca I. Hartman, MD, MPH

Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts; Department of Dermatology, Veterans Integrated Service Network (VISN-1), Jamaica Plain, Massachusetts; Correspondence to: Rebecca I. Hartman, MD, MPH, Department of Dermatology, Brigham and Women’s Hospital, 221 Longwood Avenue, Boston, MA 02215